530 related articles for article (PubMed ID: 33676969)
1. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease.
Schreiber S; Ben-Horin S; Leszczyszyn J; Dudkowiak R; Lahat A; Gawdis-Wojnarska B; Pukitis A; Horynski M; Farkas K; Kierkus J; Kowalski M; Lee SJ; Kim SH; Suh JH; Kim MR; Lee SG; Ye BD; Reinisch W
Gastroenterology; 2021 Jun; 160(7):2340-2353. PubMed ID: 33676969
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial.
D'Haens G; Reinisch W; Schreiber S; Cummings F; Irving PM; Ye BD; Kim DH; Yoon S; Ben-Horin S
Clin Drug Investig; 2023 Apr; 43(4):277-288. PubMed ID: 37004656
[TBL] [Abstract][Full Text] [Related]
4. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
5. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
Keil R; Wasserbauer M; Zádorová Z; Hajer J; Drastich P; Wohl P; Beneš M; Bojková M; Svoboda P; Konečný M; Falt P; Vaňásek T; Pešta M; Pešek F; Bouchner L; Koželuhová J; Novotný A; Bartůsková L; Špičák J
Scand J Gastroenterol; 2016 Sep; 51(9):1062-8. PubMed ID: 27002981
[TBL] [Abstract][Full Text] [Related]
6. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Clinical Outcomes After Switching from Remicade
Smits LJT; Grelack A; Derikx LAAP; de Jong DJ; van Esch AAJ; Boshuizen RS; Drenth JPH; Hoentjen F
Dig Dis Sci; 2017 Nov; 62(11):3117-3122. PubMed ID: 28667429
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.
Kim NH; Lee JH; Hong SN; Yoon H; Kang HW; Lee SH; Im JP; Cha JM; Eun CS; Kim JW; Choi CH; Park DI
J Gastroenterol Hepatol; 2019 Sep; 34(9):1523-1532. PubMed ID: 30828891
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial.
Westhovens R; Wiland P; Zawadzki M; Ivanova D; Kasay AB; El-Khouri EC; Balázs É; Shevchuk S; Eliseeva L; Stanislavchuk M; Yatsyshyn R; Hrycaj P; Jaworski J; Zhdan V; Trefler J; Shesternya P; Lee SJ; Kim SH; Suh JH; Lee SG; Han NR; Yoo DH
Rheumatology (Oxford); 2021 May; 60(5):2277-2287. PubMed ID: 33230526
[TBL] [Abstract][Full Text] [Related]
11. Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study.
Petitdidier N; Tannoury J; de'Angelis N; Gagniere C; Hulin A; Rotkopf H; Mesli F; Brunetti F; Sobhani I; Amiot A
Dig Liver Dis; 2019 Dec; 51(12):1652-1660. PubMed ID: 31718934
[TBL] [Abstract][Full Text] [Related]
12. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
13. Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trial.
Schreiber S; D'Haens G; Cummings F; Irving PM; Ye BD; Ben-Horin S; Kim DH; Jeong AL; Reinisch W
Dig Liver Dis; 2024 Feb; ():. PubMed ID: 38365502
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
Ye BD; Pesegova M; Alexeeva O; Osipenko M; Lahat A; Dorofeyev A; Fishman S; Levchenko O; Cheon JH; Scribano ML; Mateescu RB; Lee KM; Eun CS; Lee SJ; Lee SY; Kim H; Schreiber S; Fowler H; Cheung R; Kim YH
Lancet; 2019 Apr; 393(10182):1699-1707. PubMed ID: 30929895
[TBL] [Abstract][Full Text] [Related]
16. Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.
Buer LC; Moum BA; Cvancarova M; Warren DJ; Medhus AW; Høivik ML
J Crohns Colitis; 2017 Mar; 11(3):297-304. PubMed ID: 27660339
[TBL] [Abstract][Full Text] [Related]
17. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.
Fiorino G; Manetti N; Armuzzi A; Orlando A; Variola A; Bonovas S; Bossa F; Maconi G; DʼIncà R; Lionetti P; Cantoro L; Fries W; Annunziata ML; Costa F; Terpin MM; Biancone L; Cortelezzi CC; Amato A; Ardizzone S; Danese S; Guidi L; Rizzuto G; Massella A; Andriulli A; Massari A; Lorenzon G; Ghione S; Kohn A; Ventra A; Annese V;
Inflamm Bowel Dis; 2017 Feb; 23(2):233-243. PubMed ID: 28092307
[TBL] [Abstract][Full Text] [Related]
18. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
[TBL] [Abstract][Full Text] [Related]
19. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T
Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU.
Shirley M
Clin Drug Investig; 2021 Dec; 41(12):1099-1107. PubMed ID: 34727347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
